PACIFIC: Overall Survival with Durvalumab versus Placebo after Chemoradiotherapy in Stage III NSCLC

被引：3
|
作者：
Raben, D. [1 ]
Faivre-Finn, C. [2 ]
Spigel, D. [3 ]
Daniel, D. [3 ,4 ]
Villegas, A. [5 ]
Vincente, D. [6 ]
Hui, R. [7 ,8 ]
Carpeno, J. de Castro [9 ]
Murakami, S. [10 ]
Paz-Ares, L. [11 ,12 ]
Ozguroglu, M. [13 ]
Kurata, T. [14 ]
Chiappori, A. [15 ]
Lee, K. H. [16 ]
de Wit, M. [17 ]
Poole, L. [18 ]
Wadsworth, C. [19 ]
Dennis, P. A. [20 ]
Antonia, S. J. [15 ]
机构：
[1] Univ Colorado, Ctr Canc, Aurora, CO USA
[2] Univ Manchester, Div Canc Sci, Manchester, Lancs, England
[3] Sarah Cannon Res Inst, Nashville, TN USA
[4] Tennessee Oncol, Chattanooga, TN USA
[5] Canc Specialists North Florida, Jacksonville, FL USA
[6] Hosp Univ Virgen Macarena, Seville, Spain
[7] Westmead Hosp, Sydney, NSW, Australia
[8] Univ Sydney, Sydney, NSW, Australia
[9] Hosp Univ La Paz, Madrid, Spain
[10] Kanagawa Canc Ctr, Yokohama, Kanagawa, Japan
[11] Univ Complutense, Hosp Univ Octubre 12, CiberOnc, Madrid, Spain
[12] CNIO, Madrid, Spain
[13] Istanbul Univ Cerrahpasa, Cerrahpasa Med Sch, Istanbul, Turkey
[14] Kansai Med Univ Hosp, Hirakata, Osaka, Japan
[15] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA
[16] Chungbuk Natl Univ, Chungbuk Natl Univ Hosp, Coll Med, Cheongju, South Korea
[17] Vivantes Klinikum Neukoelln, Berlin, Germany
[18] AstraZeneca, Cambridge, England
[19] AstraZeneca, Alderley Pk, England
[20] AstraZeneca, Gaithersburg, MD USA
来源：
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS | 2018年 / 102卷 / 05期
关键词：
D O I：
10.1016/j.ijrobp.2018.08.057
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
LBA10
引用
收藏
页码：1607 / 1608
页数：2
相关论文
共 50 条
  • [1] Overall Survival with Durvalumab Versus Placebo After Chemoradiotherapy in Stage III NSCLC: Updated Results from PACIFIC
    Antonia, S.
    Villegas, A.
    Daniel, D.
    Vicente, D.
    Murakami, S.
    Hui, R.
    Kurata, T.
    Chiappori, A.
    Lee, K. H.
    De Wit, M.
    Cho, B. C.
    Bourhaba, M.
    Quantin, X.
    Tokito, T.
    Mekhail, T.
    Planchard, D.
    Kim, Y.
    Karapetis, C.
    Hiret, S.
    Ostoros, G.
    Kubota, K.
    Gray, J.
    Paz-Ares, L.
    Carpeno, J. De Castro
    Faivre-Finn, C.
    Reck, M.
    Vansteenkiste, J.
    Spigel, D.
    Wadsworth, C.
    Taboada, M.
    Dennis, P.
    Ozguroglu, M.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S184 - S184
  • [2] Overall Survival with Durvalumab versus Placebo after simultaneous Stage III Chemoradiotherapy NSCLC: Updated Data from the PACIFIC Study
    De Wit, M.
    Schulz, C.
    Laak, E.
    Wolff, T.
    Rueckert, A.
    Faehling, M.
    Fischer, J. R.
    Reck, M.
    STRAHLENTHERAPIE UND ONKOLOGIE, 2019, 195 : S50 - S50
  • [3] Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC
    Antonia, S. J.
    Villegas, A.
    Daniel, D.
    Vicente, D.
    Murakami, S.
    Hui, R.
    Kurata, T.
    Chiappori, A.
    Lee, K. H.
    de Wit, M.
    Cho, B. C.
    Bourhaba, M.
    Quantin, X.
    Tokito, T.
    Mekhail, T.
    Planchard, D.
    Kim, Y. -C.
    Karapetis, C. S.
    Hiret, S.
    Ostoros, G.
    Kubota, K.
    Gray, J. E.
    Paz-Ares, L.
    Carpeno, J. de Castro
    Faivre-Finn, C.
    Reck, M.
    Vansteenkiste, J.
    Spigel, D. R.
    Wadsworth, C.
    Melillo, G.
    Taboada, M.
    Dennis, P. A.
    Ozguroglu, M.
    NEW ENGLAND JOURNAL OF MEDICINE, 2018, 379 (24): : 2342 - 2350
  • [4] Three-Year Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC-Update from PACIFIC
    Gray, Jhanelle E.
    Villegas, Augusto
    Daniel, Davey
    Vicente, David
    Murakami, Shuji
    Hui, Rina
    Kurata, Takayasu
    Chiappori, Alberto
    Lee, Ki Hyeong
    Cho, Byoung Chul
    Planchard, David
    Paz-Ares, Luis
    Faivre-Finn, Corinne
    Vansteenkiste, Johan F.
    Spigel, David R.
    Wadsworth, Catherine
    Taboada, Maria
    Dennis, Phillip A.
    Ozguroglu, Mustafa
    Antonia, Scott J.
    JOURNAL OF THORACIC ONCOLOGY, 2020, 15 (02) : 288 - 293
  • [5] Durvalumab after chemoradiotherapy in stage III NSCLC: 4-year survival update from the phase III PACIFIC trial
    Faivre-Finn, C.
    Vicente, D.
    Kurata, T.
    Planchard, D.
    Paz-Ares, L.
    Vansteenkiste, J. F.
    Spigel, D. R.
    Garassino, M. C.
    Reck, M.
    Senan, S.
    Naidoo, J.
    Rimner, A.
    Wu, Y-L.
    Gray, J. E.
    Ozguroglu, M.
    Lee, K. H.
    Newton, M.
    Wang, L.
    Thiyagarajah, P.
    Antonia, S. J.
    ANNALS OF ONCOLOGY, 2020, 31 : S1178 - S1179
  • [6] Four-Year Survival With Durvalumab After Chemoradiotherapy in Stage III NSCLC-an Update From the PACIFIC Trial
    Faivre-Finn, Corinne
    Vicente, David
    Kurata, Takayasu
    Planchard, David
    Paz-Ares, Luis
    Vansteenkiste, Johan F.
    Spigel, David R.
    Garassino, Marina C.
    Reck, Martin
    Senan, Suresh
    Naidoo, Jarushka
    Rimner, Andreas
    Wu, Yi-Long
    Gray, Jhanelle E.
    Ozguroglu, Mustafa
    Lee, Ki H.
    Cho, Byoung C.
    Kato, Terufumi
    de Wit, Maike
    Newton, Michael
    Wang, Lu
    Thiyagarajah, Piruntha
    Antonia, Scott J.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (05) : 860 - 867
  • [7] Durvalumab After Chemoradiotherapy for Patients With Unresectable Stage III NSCLC: The PACIFIC-R Study
    Zhao, Binghao
    Li, Huanzhang
    Ma, Wenbin
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (04) : e38 - e39
  • [8] Real-world outcomes with durvalumab after chemoradiotherapy in patients with unresectable stage III NSCLC: interim analysis of overall survival from PACIFIC-R
    Filippi, A. R.
    Bar, J.
    Chouaid, C.
    Christoph, D. C.
    Field, J. K.
    Fietkau, R.
    Garassino, M. C.
    Garrido, P.
    Haakensen, V. D.
    Kao, S.
    Markman, B.
    Mcdonald, F.
    Mornex, F.
    Moskovitz, M.
    Peters, S.
    Sibille, A.
    Siva, S.
    Heuvel, M. van den
    Vercauter, P.
    Anand, S.
    Chander, P.
    Licour, M.
    Lima, A. R. de
    Qiao, Y.
    Girard, N.
    ESMO OPEN, 2024, 9 (06)
  • [9] 5-Year Survival Data of Durvalumab after Chemoradiotherapy for unresectable Stage III NSCLC - an Update from the PACIFIC Study
    de Wit, M.
    Spigel, D.
    Faivre-Finn, C.
    Gray, J.
    Vicente, D.
    Planchard, D.
    Paz-Ares, L.
    Vansteenkiste, J.
    Garassino, M.
    Hui, R.
    Quantin, X.
    Rimner, A.
    Wu, Y. -L.
    Ozguroglu, M.
    Lee, K. H.
    Kato, T.
    Macpherson, E.
    Newton, M.
    Thiyagarajah, P.
    Antonia, S.
    Reck, M.
    STRAHLENTHERAPIE UND ONKOLOGIE, 2021, 197 (SUPPL 1) : S8 - S9
  • [10] 5-year survival outcomes with durvalumab after chemoradiotherapy in unresectable Stage III NSCLC - an update from the PACIFIC trial
    de Wit, M.
    Spigel, D. R.
    Faivre-Finn, C.
    Gray, J. E.
    Vicente, D.
    Planchard, D.
    Paz-Ares, L.
    Vansteenkiste, J. F.
    Garassino, M. C.
    Hui, R.
    Quantin, X.
    Rimner, A.
    Wu, Y. -L
    Oezgueroglu, M.
    Lee, K. H.
    Kato, T.
    Macpherson, E.
    Newton, M.
    Thiyagarajah, P.
    Antonia, S. J.
    Reck, M.
    ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 : 109 - 110
12345